Manufacturing News of Note—AveXis goes deeper on Zolgensma manufacturing; 76B opioid pills manufactured

stocks
According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. (Pixabay)

Here is some news of note for the week: 

> Catalent Biologics and Novartis’ company AveXis have struck a long-term deal in which the biotech will have dedicated manufacturing space at a Catalent facility for the production of AveXis' Zolgensma, its newly approved gene therapy for spinal muscular atrophy. Release 

> Data recently released as part of a civil action show that U.S. drugmakers manufactured 76 billion oxycodone and hydrocodone pills from 2006 through 2012 as the opioid epidemic spread. Story

> According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. Release

 


 

Suggested Articles

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

AstraZeneca and Oxford BioMedica have inked a deal to produce commercial and clinical supply of the University of Oxford's COVID-19 shot hopeful.